Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults

MLA

Jason C. Martin, et al. “Immunogenicity, Lot Consistency, and Extended Safety of RVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.” The Journal of Infectious Diseases, vol. 220, July 2019, pp. 1127–35. EBSCOhost, https://doi.org/10.1093/infdis/jiz241.

APA

Jason C. Martin, Matthew T. Onorato, Beth-Ann Coller, Kenneth Liu, Rituparna Das, V Study Team, Rick Nichols, Scott A. Halperin, Rebecca J. Grant-Klein, Jakub K. Simon, & Frans A. Helmond. (2019). Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. The Journal of Infectious Diseases, 220, 1127–1135. https://doi.org/10.1093/infdis/jiz241

Chicago

Jason C. Martin, Matthew T. Onorato, Beth-Ann Coller, Kenneth Liu, Rituparna Das, V Study Team, Rick Nichols, et al. 2019. “Immunogenicity, Lot Consistency, and Extended Safety of RVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.” The Journal of Infectious Diseases 220 (July): 1127–35. doi:10.1093/infdis/jiz241.